Zymeworks Finalizes $2.6B Theravance Biopharma Acquisition…

Event summary

Zymeworks completed its acquisition of Theravance Biopharma on September 23, 2026.
The deal expands Zymeworks' portfolio with commercial and near-commercial assets like YUPELRI® and Ziihera®.
Zymeworks will host a conference call on September 28, 2026, to discuss transaction details.
Theravance Biopharma's TRELEGY® royalty interests are part of the acquired assets.

The big picture

Zymeworks' acquisition of Theravance Biopharma aligns with its strategy to build a diversified biotechnology company with both innovative R&D and growing commercial revenue streams. The deal positions Zymeworks to leverage Theravance's commercial assets, such as YUPELRI®, while integrating its internal R&D capabilities to drive long-term value creation. This move reflects a broader industry trend of biotech firms consolidating to enhance their portfolios and achieve sustainable growth.

What we're watching

Integration Challenges: How Zymeworks will manage the operational and cultural integration of Theravance Biopharma's assets.
Revenue Growth: Whether the acquisition will accelerate Zymeworks' revenue growth through expanded commercial and royalty-based cash flows.
Pipeline Development: The pace at which Zymeworks advances its diverse pipeline of novel biotherapeutics using Theravance's assets.